The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights

16 Pages Posted: 30 May 2017

See all articles by Pedro Matos

Pedro Matos

University of Virginia - Darden School of Business; European Corporate Governance Institute (ECGI)

Dmitriy Aleyev

affiliation not provided to SSRN

Abstract

This case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme's pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (CVR). Was a CVR the magical solution to bridging the valuation gap?

Excerpt

UVA-F-1715

Oct. 22, 2014

THE SANOFI-AVENTIS ACQUISITION OF GENZYME:

CONTINGENT VALUE RIGHTS

At the end of January 2011, Henri Termeer, the CEO of Genzyme, and Chris Viehbacher, the CEO of Sanofi-Aventis (Sanofi), were both attending the World Economic Forum, a gathering of chief executives, heads of state, and other influential figures at the ski resort in Davos, Switzerland. The advisers of the two firms had spent countless hours discussing merger deal alternatives, and the private meeting between the CEOs was expected to close these negotiations.

Sanofi, a large French pharmaceutical company, had first expressed its interest in acquiring Genzyme in the summer of 2010. Termeer had led Genzyme for more than 25 years, overseeing its growth from an entrepreneurial venture to a top U.S. biotechnology firm. The main reasons Sanofi was attracted to Genzyme were its lucrative drug business that focused on hard-to-copy genetic diseases and its pipeline of drugs under development (Exhibit 1). Sanofi was fighting a looming drop in its revenues due to the patent expirations of several of its blockbuster drugs. The Genzyme acquisition would shift the focus of Sanofi's portfolio toward biopharma, an area in which the firm lagged behind its competitors.

. . .

Keywords: M&A valuation, market potential, biotechnology, estimates, contingent value right

Suggested Citation

Matos, Pedro and Aleyev, Dmitriy, The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights. Darden Case No. UVA-F-1715. Available at SSRN: https://ssrn.com/abstract=2974524

Pedro Matos (Contact Author)

University of Virginia - Darden School of Business ( email )

University of Virginia
P.O. Box 6550
Charlottesville, VA 22906-6550
United States
434 243 8998 (Phone)
434 924 0726 (Fax)

HOME PAGE: http://www.darden.virginia.edu/faculty-research/directory/pedro-matos/

European Corporate Governance Institute (ECGI) ( email )

c/o ECARES ULB CP 114
B-1050 Brussels
Belgium

Dmitriy Aleyev

affiliation not provided to SSRN

No Address Available

Register to save articles to
your library

Register

Paper statistics

Downloads
0
Abstract Views
281
PlumX Metrics